A Clinical Trial to Evaluate PCS499 in Treating Ulcerations in Patients Who Have Necrobiosis Lipoidica
Study sponsor: Processa Pharmaceuticals
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2023-02-28Actual
Enrollment · participants4Actual
Source updated2023-08-03Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.